Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies Initially Diagnosed as Immune Thrombocytopenia and Reclassified After 10 Years: Diagnostic Pitfall Revealed by a Family History.

Internal medicine (Tokyo, Japan)·2026

Same author

Continuous Glucose Monitoring for Detecting Hypoglycemia During Maintenance Therapy for Acute Lymphoblastic Leukemia.

Pediatrics international : official journal of the Japan Pediatric Society·2026

Same author

A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same author

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026

Same author

mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac).

Molecular therapy. Oncology·2026

Same author

Trends, Demographic Characteristics, and Seasonal Patterns of Nonoperative and Operative Reduction for Intussusception: A Preliminary Nationwide Claims-Based Analysis from 2014 to 2023 in Japan.

Internal medicine (Tokyo, Japan)·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

[Adoptive cell therapy for solid tumors].

Kenichi Sakamoto¹, Shigeki Yagyu²

¹Department of Pediatrics, Shinshu University School of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology

|August 4, 2024

Summary

Adoptive cell therapy (ACT) shows promise for solid tumors, but challenges like antigen identification and tumor microenvironment interactions need addressing. This review explores current data and future strategies for advancing ACT in solid tumors.

Keywords:

Adoptive cell therapy Chimeric antigen receptor Solid tumor T cell receptor

More Related Videos

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jun 18, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Chimeric antigen receptor (CAR) T-cell therapy has transformed refractory/relapsed (R/R) hematologic malignancies treatment.
Six CAR T-cell products are approved for B-cell tumors and multiple myeloma.
Adoptive cell therapy (ACT) faces significant hurdles in solid tumors.

Purpose of the Study:

To review clinical trial data for ACT in solid tumors.
To elucidate the current landscape of ACT development for solid tumors.
To outline the trajectory and integrative approaches for ACT in solid tumors.

Main Methods:

Review of existing clinical trial data on ACT for solid tumors.
Analysis of challenges in ACT for solid tumors.
Exploration of strategies to overcome the tumor microenvironment.

Main Results:

ACT for solid tumors is challenged by lack of tumor-specific antigens.
Inefficient T-cell trafficking and infiltration into the tumor microenvironment are key issues.
Immunosuppressive signals in the tumor milieu induce T-cell dysfunction.

Conclusions:

ACT holds potential for solid tumors but requires overcoming significant biological barriers.
Future strategies must address antigen targeting, T-cell trafficking, and the immunosuppressive tumor microenvironment.
Integrative approaches are crucial for advancing ACT in solid tumor treatment.